目次

Table of Content

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Type
1.1.3. Source
1.1.4. Indication
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Recombinant Protein Therapeutics CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Recombinant Protein Therapeutics
3.2.1.2. Rising Adoption of Biologics and Biosimilars
3.2.1.3. Technological Innovations Pertaining to the Development of Novel Recombinant Protein Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory Hurdles
3.2.2.2. Challenges Related to Quality Control
3.3. Recombinant Protein Therapeutics CDMO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & TrendAnalysis
4.1. Recombinant Protein Therapeutics CDMO Market, By Type: Segment Dashboard
4.2. Recombinant Protein Therapeutics CDMO Market, By Type: Movement Analysis
4.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Type, 2018 - 2030
4.3.1. Growth Hormones
4.3.1.1. Growth Hormones Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.2. Interferons
4.3.2.1. Interferons Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.3. Vaccines
4.3.3.1. Vaccines Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.4. Immunostimulating Agents
4.3.4.1. Immunostimulating Agents Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
4.3.5. Others
4.3.5.1. Others Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Tred Analysis
5.1. Recombinant Protein Therapeutics CDMO Market, By Source: Segment Dashboard
5.2. Recombinant Protein Therapeutics CDMO Market, By Source: Movement Analysis
5.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Source, 2018 - 2030
5.3.1. Mammalian Systems
5.3.1.1. Mammalian Systems Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
5.3.2. Microbial Systems
5.3.2.1. Microbial Systems Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)
5.3.3. Others
5.3.3.1. Others Recombinant Protein Therapeutics CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates &Trend Analysis
6.1. Recombinant Protein Therapeutics CDMO Market, By Indication: Segment Dashboard
6.2. Recombinant Protein Therapeutics CDMO Market, By Indication: Movement Analysis
6.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030
6.3.1. Oncology
6.3.1.1. Oncology Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.2. Infectious Diseases
6.3.2.1. Infectious Diseases Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.3. Immunological Disorders
6.3.3.1. Immunological Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.4. Metabolic Disorders
6.3.4.1. Metabolic Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.5. Haematological Disorders
6.3.5.1. Haematological Disorders Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Recombinant Protein Therapeutics CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Tend Analysis
7.1. Regional Market Share Analysis, 2022 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2022
8.2. Company Profiles
8.2.1. Richter-Helm BioLogics
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Service Benchmarking
8.2.1.4. Strategic Initiatives
8.2.2. Lonza
8.2.2.1. Company Overview
8.2.2.2. Financial Performance
8.2.2.3. Service Benchmarking
8.2.2.4. Strategic Initiatives
8.2.3. Catalent, Inc
8.2.3.1. Company Overview
8.2.3.2. Financial Performance
8.2.3.3. Service Benchmarking
8.2.3.4. Strategic Initiatives
8.2.4. FUJIFILM Diosynth Biotechnologies
8.2.4.1. Company Overview
8.2.4.2. Financial Performance
8.2.4.3. Service Benchmarking
8.2.4.4. Strategic Initiatives
8.2.5. WuXi Biologics
8.2.5.1. Company Overview
8.2.5.2. Financial Performance
8.2.5.3. Service Benchmarking
8.2.5.4. Strategic Initiatives
8.2.6. Curia Global, Inc.
8.2.6.1. Company Overview
8.2.6.2. Financial Performance
8.2.6.3. Service Benchmarking
8.2.6.4. Strategic Initiatives
8.2.7. Batavia Biosciences B.V.
8.2.7.1. Company Overview
8.2.7.2. Financial Performance
8.2.7.3. Service Benchmarking
8.2.7.4. Strategic Initiatives
8.2.8. HALIX B.V.
8.2.8.1. Company Overview
8.2.8.2. Financial Performance
8.2.8.3. Service Benchmarking
8.2.8.4. Strategic Initiatives
8.2.9. AGC Biologics
8.2.9.1. Company Overview
8.2.9.2. Financial Performance
8.2.9.3. Service Benchmarking
8.2.9.4. Strategic Initiatives
8.2.10. Enzene Biosciences
8.2.10.1. Company Overview
8.2.10.2. Financial Performance
8.2.10.3. Service Benchmarking
8.2.10.4. Strategic Initiatives

List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 4 North America Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 5 North America Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 6 North America Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 7 U.S. Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 8 U.S. Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 9 U.S. Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 10 Canada Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 11 Canada Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 12 Canada Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 13 Europe Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 14 Europe Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 15 Europe Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 16 Europe Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 17 U.K. Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 18 U.K. Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 19 U.K. Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 20 Germany Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 21 Germany Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 22 Germany Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 23 France Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 24 France Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 25 France Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 26 Italy Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 27 Italy Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 28 Italy Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 29 Spain Recombinant Protein Therapeutics CDMO market, by Source type, 2018 - 2030 (USD Million)
Table 30 Spain Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 31 Spain Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 32 Denmark Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 33 Denmark Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 34 Denmark Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 35 Sweden Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 36 Sweden Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 37 Sweden Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 38 Norway Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 39 Norway Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 40 Norway Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 45 China Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 46 China Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 47 China Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 48 Japan Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 49 Japan Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 50 Japan Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 51 India Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 52 India Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 53 India Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 54 Australia Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 55 Australia Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 56 Australia Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 57 South Korea Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 58 South Korea Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 59 South Korea Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 60 Thailand Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 61 Thailand Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 62 Thailand Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 63 Latin America Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 64 Latin America Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 65 Latin America Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 66 Latin America Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 67 Brazil Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 68 Brazil Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 69 Brazil Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 70 Mexico Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 71 Mexico Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 72 Mexico Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 73 Argentina Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 74 Argentina Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 75 Argentina Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 76 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by region, 2018 - 2030 (USD Million)
Table 77 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 78 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 79 Middle East and Africa Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 80 South Africa Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 81 South Africa Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 82 South Africa Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 86 UAE Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 87 UAE Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 88 UAE Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)
Table 89 Kuwait Recombinant Protein Therapeutics CDMO market, by Source, 2018 - 2030 (USD Million)
Table 90 Kuwait Recombinant Protein Therapeutics CDMO market, by Type, 2018 - 2030 (USD Million)
Table 91 Kuwait Recombinant Protein Therapeutics CDMO market, by Indication, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modelling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary research pattern
Fig. 8 Primary interviews in North America
Fig. 9 Primary interviews in Europe
Fig. 10 Primary interviews in Asia Pacific
Fig. 11 Primary interviews in Latin America
Fig. 12 Primary interviews in MEA
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Segment Snapshot
Fig. 16 Competitive Landscape Snapshot
Fig. 17 Recombinant Protein Therapeutics CDMO market segmentation
Fig. 18 Parent market outlook (2022)
Fig. 19 Related/ancillary market outlook (2022)
Fig. 20 Market driver relevance analysis (Current & future impact)
Fig. 21 Market restraint relevance analysis (Current & future impact)
Fig. 22 Porter’s five forces analysis
Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 24 Recombinant Protein Therapeutics CDMO Market Type outlook: Segment dashboard
Fig. 25 Recombinant Protein Therapeutics CDMO :Type movement analysis
Fig. 26 Growth Hormones market, 2018 - 2030 (USD Million)
Fig. 27 Interferons market, 2018 - 2030 (USD Million)
Fig. 28 Vaccines market, 2018 - 2030 (USD Million)
Fig. 29 Immunostimulating Agents market, 2018 - 2030 (USD Million)
Fig. 30 Others market, 2018 - 2030 (USD Million)
Fig. 31 Recombinant Protein Therapeutics CDMO Market Source outlook: Segment dashboard
Fig. 32 Recombinant Protein Therapeutics CDMO : Source type movement analysis
Fig. 33 Mammalian Systems market, 2018 - 2030 (USD Million)
Fig. 34 Microbial Systems market, 2018 - 2030 (USD Million)
Fig. 35 Others market, 2018 - 2030 (USD Million)
Fig. 36 Recombinant Protein Therapeutics CDMO market Indication outlook: Segment dashboard
Fig. 37 Recombinant Protein Therapeutics CDMO market: Indication movement analysis
Fig. 38 Oncology market, 2018 - 2030 (USD Million)
Fig. 39 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 40 Immunological Disorders market, 2018 - 2030 (USD Million)
Fig. 41 Metabolic Disorders market, 2018 - 2030 (USD Million)
Fig. 42 Haematological Disorders market, 2018 - 2030 (USD Million)
Fig. 43 Others market, 2018 - 2030 (USD Million)
Fig. 44 Regional marketplace: Segment dashboard
Fig. 45 Regional outlook, 2022 & 2030
Fig. 46 North America market, 2018 - 2030 (USD Million)
Fig. 47 U.S. market, 2018 - 2030 (USD Million)
Fig. 48 Canada market, 2018 - 2030 (USD Million)
Fig. 49 Europe market, 2018 - 2030 (USD Million)
Fig. 50 Germany market, 2018 - 2030 (USD Million)
Fig. 51 UK market, 2018 - 2030 (USD Million)
Fig. 52 France market, 2018 - 2030 (USD Million)
Fig. 53 Italy market, 2018 - 2030 (USD Million)
Fig. 54 Spain market, 2018 - 2030 (USD Million)
Fig. 55 Denmark market, 2018 - 2030 (USD Million)
Fig. 56 Sweden market, 2018 - 2030 (USD Million)
Fig. 57 Norway market, 2018 - 2030 (USD Million)
Fig. 58 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 59 China market, 2018 - 2030 (USD Million)
Fig. 60 Japan market, 2018 - 2030 (USD Million)
Fig. 61 India market, 2018 - 2030 (USD Million)
Fig. 62 Australia market, 2018 - 2030 (USD Million)
Fig. 63 Thailand market, 2018 - 2030 (USD Million)
Fig. 64 South Korea market, 2018 - 2030 (USD Million)
Fig. 65 Latin America market, 2018 - 2030 (USD Million)
Fig. 66 Brazil market, 2018 - 2030 (USD Million)
Fig. 67 Mexico market, 2018 - 2030 (USD Million)
Fig. 68 Argentina market, 2018 - 2030 (USD Million)
Fig. 69 Middle East & Africa market, 2018 - 2030 (USD Million)
Fig. 70 South Africa market, 2018 - 2030 (USD Million)
Fig. 71 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 72 UAE market, 2018 - 2030 (USD Million)
Fig. 73 Kuwait market, 2018 - 2030 (USD Million)